{"entity":{"id":"nct03568656","kind":"trial","name":"Study to Evaluate CCS1477 in Advanced Tumours","aka":[],"tldr":"A phase 1/2 trial of Inobrodib run by CellCentric Ltd., completed.","summary":"Study to Evaluate CCS1477 in Advanced Tumours is a phase 1/2 interventional study registered as NCT03568656 by CellCentric Ltd., with 219 participants enrolled, started 2018-07-23, primary completion reached 2025-07-06. Conditions recorded: Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors. Interventions recorded: CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT03568656","url":"https://clinicaltrials.gov/study/NCT03568656"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["inobrodib"],"companies":["cellcentric"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03568656","phase":"1/2","setting":"An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.","sponsor":"CellCentric Ltd.","enrolled":219,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03568656/","neighbours":{"drug":[{"id":"inobrodib","kind":"drug","name":"Inobrodib","route":"/drugs/inobrodib/"}],"company":[{"id":"cellcentric","kind":"company","name":"CellCentric","route":"/companies/cellcentric/"}]}}